We're applying our scientific expertise and proprietary technology to create and deliver next generation RNA therapeutics.

Our preclinical drug development pipeline is initially focused in three key therapeutic areas with high potential to deliver meaningful patient results.


We are developing immuno-oncology treatments and vaccines to uniquely stimulate a patient's immune system for the specific destruction of cancer cells present in the body.

Genetic Disorders

We are developing therapeutics to address genetic disorders.

Infectious Disease

We are advancing next generation RNA vaccines to help provide significant protection against common infectious diseases currently plaguing millions of people around the globe.